ArticleInternational journal of epidemiology2026
Duration of vaccine-induced immunity following MMR2 vaccination in a measles and rubella-eliminated country.
Article in International journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe measles, mumps, and rubella (MMR) vaccine is generally considered to provide lifelong immunity against measles and rubella. However, occasional measles outbreaks in countries with high vaccine coverage have raised concerns about waning immunity. In this study, we aimed to estimate the duration of vaccine-induced immunity following MMR2 vaccination in settings where measles and rubella have been eliminated.
methodsUsing 2019 national serosurvey data, this study estimated antibody waning (decay) rates for each antigen after MMR2 vaccination, with age as a proxy for time since vaccination. In South Korea, MMR2 coverage has exceeded 95% from the 1995 birth cohort, and no significant measles or rubella outbreaks have occurred since 2001, allowing for homogeneous cohorts. Additionally, the time required for the geometric mean titers of each antibody to reach the seronegative cutoff levels was calculated.
resultsThe average antibody decay rates for MMR were 8.71%, 12.02%, and 5.48% per year, respectively, after MMR2 vaccination. The duration of vaccine-induced immunity was estimated to be 19 years for measles, 9.71 years for mumps, and 31.57 years for rubella when equivocal results were considered negative. If equivocal results were considered positive, the duration would be 27.32 years for measles, 15.25 years for mumps, and 39.77 years for rubella.
conclusionHere, we found that individuals who have not experienced natural infection exhibited age-dependent waning of vaccine-induced immunity. While vaccination remains the most effective way to prevent disease, continued vigilance is necessary even in countries with high vaccine coverage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.